Oncotelic Presents at the Precision in Drug Discovery Summit
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has made significant strides in the field of oncology, recently presenting at the notable Precision in Drug Discovery & Preclinical Summit held in San Diego. Dr. Wen-Han Chang and Dr. Tara Zand represented the company, highlighting the Sapu Bio pipeline centered around TGFB2 therapeutics.
Expert Insights into Cancer Therapies
Dr. Chang and Dr. Zand are recognized experts in nanomedicine and precision drug development, passionate about finding cures for challenging cancers like pancreatic and brain cancers. Their involvement at the summit underscores Oncotelic's commitment to innovation in cancer treatment.
Oncotelic's Unique Approach to Oncology
Founded back in 1988 as OXiGENE, Inc., Oncotelic has evolved significantly over the decades. Reincorporated in Delaware in 1992 and rebranding in 2020 to its current name, Oncotelic is dedicated to harnessing its extensive expertise in oncology to enhance treatment outcomes for patients with particularly rare cancers, especially pediatric cases.
Significant Programs and Designations
Among its initiatives, Oncotelic has garnered rare pediatric designation for Diffuse Intrinsic Pontine Glioma (DIPG) through its product OT-101. Additionally, it focuses on melanoma treatment via CA4P and Acute Myeloid Leukemia with OXi 4503. These designations reflect Oncotelic's dedication to addressing significant gaps in the treatment market.
Innovative Developments and Technologies
Oncotelic's acquisition of PointR Data Inc. in late 2019 marked a pivotal expansion, positioning the company to build an AI-driven biotechnology platform. Furthermore, in the fourth quarter of 2021, the company acquired AL-101, designed for intranasal delivery of apomorphine, targeting conditions such as Parkinson’s Disease and various sexual disorders. These conditions represent a broad demographic needing effective treatment solutions.
Future Directions and Regulatory Aspects
As Oncotelic navigates the complex landscape of biotechnology, they aim to push through various clinical stages while ensuring compliance with regulatory frameworks. The company's Annual Report filed in April outlines critical future ambitions, focusing on pioneering treatments that resonate with both medical professionals and patients alike, reflecting their core mission.
Contacting Oncotelic for More Information
If you wish to learn more about Oncotelic Therapeutics, Inc. and their innovative approaches to tackling formidable cancers, you can reach out to their Investor Relations team directly at ir@oncotelic.com.
Frequently Asked Questions
What is Oncotelic Therapeutics known for?
Oncotelic Therapeutics is recognized for its innovative approaches in oncology, focusing on developing new therapeutics for challenging cancers.
Who presented at the Precision in Drug Discovery Summit?
Dr. Wen-Han Chang and Dr. Tara Zand presented Oncotelic's therapeutic pipelines at the summit.
What is the significance of TGFB2 therapeutics?
TGFB2 therapeutics represents a key focus area for Oncotelic, aiming to enhance treatment outcomes for cancer patients, particularly in hard-to-treat cases.
What are AL-101’s intended treatments?
AL-101 is aimed at treating Parkinson’s Disease, erectile dysfunction, female sexual disorders, and hypoactive sexual desire disorder.
How can I contact Oncotelic for more information?
You can reach Oncotelic Therapeutics through their Investor Relations email at ir@oncotelic.com.